Table 2.

Summary of each model aspect evaluated during the development and sensitivity phases, with performance measures

Phase	Model number	Description	TRSS	Number (%) of observations in predicted interval
Development	Base	Previously published model, with updated $f^{\ast }$ value of 33.6	176.2	27 (13%)
	1	40 h parasite life cycle	185.5	27 (13%)
	2	Body fluid estimated by weight. BV = 0.07 × weight, ECF = 0.2 × weight	171.5	30 (14%)
	3	Body fluid estimated by weight and sex. BV = 0.07 × weight, ECF = 0.245 × weight for males and ECF = 0.22 × weight for females	164.2	37 (18%)
	4	Elimination half-life estimate of 1.67 days	131.1	43 (21%)
	5	Elimination half-life lower bound of 95% CI of 1.11 days	102.7	51 (25%)
	6	Elimination half-life upper bound of 95% CI of 3.40 days	172.7	28 (13%)
	7 (Final)	Body fluid estimated by weight and sex. BV = 0.07 × weight, ECF = 0.245 × weight for males and ECF = 0.22 × weight for females and elimination half-life of 1.67	122.6	57 (27%)
Sensitivity	8	Final model with the upper confidence bound of the 95% CI for $f^{\ast }$, $f=42.18$	141.1	49 (24%)
	9	Final model with the lower confidence bound of the 95% CI for $f^{\ast }$, $f=24.97$	104.8	64 (31%)
	10	Final model with the upper confidence bound of the 95% CI for half-life, 3.40 days	160.9	37 (18%)
	11	Final model with the lower bound of the 95% CI for half-life, 1.11 days	97.2	57 (27%)

Performance measures evaluated during the development and sensitivity phases were the total residual sum of squares (TRSS) and the number (%) of PfHRP2 observations within the range of the predicted minimum and maximum PfHRP2 concentrations as generated from the models. Model 7 is considered the final model (bold)